"Remdesivir" (brand name of licensed USAMRID patent) appeared in the "public domain" ostensibly to treat ebola in 2014 and again 2018 to present, I might have mentioned more than once.

Neither it nor hydroxycholorquine (compound generic) is approved by FDA for treatment of COVID-19. And both are EAU authorized by FDA for ("off-label") treatment of COVID-9, cover-story, clinical trial of "investigational" (formerly known as "experimental") drug. NIAID's trial design (linked above) is suspiciously comprehensive and detailed, given purported inexperience with this "biologic" drug's active ingredients, forensic disposition, and therapeutic efficacy.

FDA's public notice alerts prospective trial-subjects and parents [?!] to known and unspecified side-effects that may occur with application. While such notice does not represent an informed consent agreement, I note with interest that the US Congress is preparing to indemnify any and all commercial establishments from tort claims relating SARS-COv-2 infection to exposure on premises. One several "trial balloons" floated by press in last three weeks, U.S. Republicans push for coronavirus lawsuit immunity for business, to which no opposition has appeared.